Cervical cancer control in HIV-infected women: Past, present and future

Rahel G. Ghebre, Surbhi Grover, Melody J. Xu, Linus T. Chuang, Hannah Simonds

Research output: Contribution to journalReview articlepeer-review

103 Scopus citations


Since the initial recognition of acquired immunodeficiency syndrome (AIDS) in 1981, an increased burden of cervical cancer was identified among human immunodeficiency virus (HIV)-positive women. Introduction of antiretroviral therapy (ART) decreased risks of opportunistic infections and improved overall survival. HIV-infected women are living longer. Introduction of the human papillomavirus (HPV) vaccine, cervical cancer screening and early diagnosis provide opportunities to reduce cervical cancer associated mortality. In line with 2030 Sustainable Development Goals to reduce mortality from non-communicable diseases, increased efforts need to focus on high burden countries within sub-Saharan Africa (SSA). Despite limitations of resources in SSA, opportunities exist to improve cancer control. This article reviews advancements in cervical cancer control in HIV-positive women.

Original languageEnglish (US)
Pages (from-to)101-108
Number of pages8
JournalGynecologic Oncology Reports
StatePublished - Aug 2017

Bibliographical note

Publisher Copyright:
© 2017 The Authors


  • Cervical cancer
  • Cervical cancer screening
  • Chemoradiation therapy
  • Human immunodeficiency virus (HIV)
  • Limited resource setting


Dive into the research topics of 'Cervical cancer control in HIV-infected women: Past, present and future'. Together they form a unique fingerprint.

Cite this